MODERATE TO SEVERE ATOPIC DERMATITIS
Clinical trials for MODERATE TO SEVERE ATOPIC DERMATITIS explained in plain language.
Never miss a new study
Get alerted when new MODERATE TO SEVERE ATOPIC DERMATITIS trials appear
Sign up with your email to follow new studies for MODERATE TO SEVERE ATOPIC DERMATITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Real-World dupixent study shows promise for eczema sufferers
Disease control CompletedThis study followed 305 Canadian patients aged 6 and older with moderate-to-severe atopic dermatitis (eczema) who were prescribed Dupixent as part of their routine care. Researchers measured how many patients saw at least a 75% improvement in their eczema symptoms after 6, 12, an…
Matched conditions: MODERATE TO SEVERE ATOPIC DERMATITIS
Sponsor: Sanofi • Aim: Disease control
Last updated May 26, 2026 09:30 UTC
-
New study shows dupilumab works for eczema in darker skin tones
Disease control CompletedThis study looked at how well the drug dupilumab works for people with skin of color who have moderate-to-severe eczema (atopic dermatitis). 124 adolescents and adults received the drug for 24 weeks. The main goal was to see if their eczema improved by at least 75%, and the study…
Matched conditions: MODERATE TO SEVERE ATOPIC DERMATITIS
Phase: PHASE4 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
Eczema drug SHR-1819 put to the test in extended trial
Disease control CompletedThis study looked at the long-term safety and effectiveness of the drug SHR-1819 in 79 adults with moderate to severe atopic dermatitis (eczema) who had already taken part in earlier studies of the same drug. Researchers monitored side effects and how well the drug controlled the…
Matched conditions: MODERATE TO SEVERE ATOPIC DERMATITIS
Phase: PHASE2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 18, 2026 12:12 UTC
-
New shot shows promise for severe eczema sufferers
Symptom relief CompletedThis study tested an experimental injection called SHR-1819 in 158 adults with moderate to severe atopic dermatitis (eczema). The goal was to see if it safely reduces skin redness, itching, and rash. Participants received either the drug or a placebo, and doctors measured improve…
Matched conditions: MODERATE TO SEVERE ATOPIC DERMATITIS
Phase: PHASE2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated May 19, 2026 11:48 UTC
-
Eczema drug may weaken vaccine protection, study finds
Knowledge-focused CompletedThis study looked at whether rocatinlimab, a drug for moderate-to-severe eczema, changes how well vaccines work. About 221 adults with eczema received either the drug or a placebo, then got tetanus and meningitis vaccines. The goal was to see if their immune response was differen…
Matched conditions: MODERATE TO SEVERE ATOPIC DERMATITIS
Phase: PHASE3 • Sponsor: Amgen • Aim: Knowledge-focused
Last updated May 26, 2026 09:31 UTC